EA
41
3
NDAQ
46
2
WAT
55
11
PCG
59
9
PFE
37
4
DFS
64
4
HAL
40
11
KHC
11
2
DGX
28
4
FITB
36
3
MU
42
14
PBI
30
-8
PRU
39
3
TSCO
42
4
PSA
43
6
SHW
42
5
EFX
43
3
MKC
54
3
BAC
38
3
KEY
24
2
EA
41
3
NDAQ
46
2
WAT
55
11
PCG
59
9
PFE
37
4
DFS
64
4
HAL
40
11
KHC
11
2
DGX
28
4
FITB
36
3
MU
42
14
PBI
30
-8
PRU
39
3
TSCO
42
4
PSA
43
6
SHW
42
5
EFX
43
3
MKC
54
3
BAC
38
3
KEY
24
2
Financhill
Back

Zevra Therapeutics 10K Form

Sell
44

ZVRA
Zevra Therapeutics

Last Price:
$8.58
Seasonality Move:
-0.81%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ZVRA News And Ratings

See the #1 stock for the next 7 days that we like better than ZVRA

ZVRA Financial Statistics

Sales & Book Value

Annual Sales: $27.5M
Cash Flow: $-18.1M
Price / Cash Flow: 0
Annual Sales: $1.31
Price / Book: 6.5

Profitability

EPS (TTM): -2.11000
Net Income (TTM): $-89.7M
Gross Margin: $24.5M
Return on Equity: -159.89%
Return on Assets: -56.14%

Zevra Therapeutics Earnings Forecast

Key Zevra Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for ZVRA is 89.28%.
  • The Selling, General & Administrative Expenses for ZVRA have been equal to 124.96% of Gross Profit Margin.
  • The Research & Development expenses have been 144.95% of Revenue.
  • The Interest Expense is -3.26% of Operating Income.
  • The Net Earning history of ZVRA is -167.69% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Zevra Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ZVRA
Website: zevra.com

Debt

Debt-to-Equity Ratio: 0.84
Current Ratio: 2.88
Quick Ratio: 2.82

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ZVRA Technical Analysis vs Fundamental Analysis

Sell
44
Zevra Therapeutics (ZVRA) is a Sell

Is Zevra Therapeutics a Buy or a Sell?